Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Oct 09, 2024 9:30am
62 Views
Post# 36259142

RE:RE:Medipharm Labs Big Win

RE:RE:Medipharm Labs Big Win
alleyesonme wrote: Yes, lower revenue products are being replaced with higher revenue offerings, this year pharmaceutical API (dronabinol) comprises 10% of revenue, New B2B contracts signed for increases from almost nothing to close to 900k last quarter, costs have systematically dropped two years straight. I'm pleased with the focus on international medica and API, Canadian rec market is a joke, the gov is killing the industry, Labs paid 1.8m in excise tax this year so far, meanwhile the largest players simply aren't paying excise tax with 100's of millions owing and no repercussions.   


I would agree that the last Q or so highlighted some positive things.

But, when those positive things had essentially nothing to do with the massive catalysts that the business had apparently been waiting on, then something doesn't jive.  There was never any indication that B2B or Drob was going to represent a significant uptick and thus I don't think anyone should take those lines as sustaining.  Unless we get a NR that states a nice juicy recurring Drob PO, then it's just manna from heaven.

When you look at the investor deck, the catalysts they presented have either long gone or have been long silent.  That's not a good look when your strategic outlook doesn't align with your tactical business.
<< Previous
Bullboard Posts
Next >>